SER

Serina Therapeutics' stock price has been impacted by several events. In November 2025, the company reported its Third Quarter financial results. In January 2026, the FDA cleared the IND application for SER-252, leading to a stock price increase, but the company also received a NYSE American deficiency notification. In February 2026, the first patient was enrolled in the Phase 1 registrational trial for SER-252. In March 2026, Serina secured private placement financing, causing the stock to surge, and reported full-year 2025 financial results, showing a net loss and increased operating expenses, which led to a stock price decline. Insider selling activity was also reported in March 2026. In April 2026, NYSE American accepted Serina's plan for continued listing compliance. The stock has experienced significant volatility, with a decrease since January 1, 2026, and over the past year, and shareholder dilution has been identified as a major risk.